Clinical trial
Edaravone-Sodium Ozagrel Comparative Post-Marketing Study on Acute Ischemic…
NCT00200356 · Tanabe Pharma Corporation, Industry · Completed
Key facts
| NCT number | NCT00200356 |
|---|---|
| Title | Edaravone-Sodium Ozagrel Comparative Post-Marketing Study on Acute Ischemic Stroke |
| Official title | Edaravone-Sodium Ozagrel (Thromboxane A2 Synthase Inhibitor) Comparative Post-Marketing Study on Acute Ischemic Stroke |
| Lead sponsor | Tanabe Pharma Corporation, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Cerebral Infarction |
| Intervention type | Drug |
| Interventions | Edaravone, Sodium Ozagrel |
| Enrollment | 401 |
| Start date | Aug 1, 2004 |
| Completion | Oct 1, 2006 |
| First posted | Sep 20, 2005 |
| Last update posted | Jan 7, 2026 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: